Sesen Bio gets shareholders’ approval for merger with Carisma Therapeutics

Nasdaq-listed Sesen Bio said that its stockholders have approved the previously announced merger deal with Carisma Therapeutics aimed at creating a clinical-stage biotechnology company for ... Read More